SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA has granted full approval of its Investigational Device Exemption (IDE) to conduct a new pivotal trial titled Adipose Derived ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results